Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.44 |
| ▸ | KDM4A | O75164 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20767991 | 0.86 | ALDH1A1 (0.40) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL7196384 | 0.84 | NPC1 (0.53) | ALOX5MAPTLMNANPC1ALDH1A1 | |
| SCHEMBL10596450 | 0.84 | NPSR1 (0.53) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL1769746 | 0.84 | NPSR1 (0.53) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL7985994 | 0.82 | ALDH1A1 (0.48) | ALOX5LMNANPC1ALDH1A1POLB | |
| SCHEMBL4138868 | 0.81 | NPSR1 (0.55) | ALOX5L3MBTL1MAPTLMNATDP1 | |
| SCHEMBL20591107 | 0.81 | TBXAS1 (0.45) | MAPTLMNAPOLBHDAC3HDAC4 | |
| SCHEMBL836988 | 0.80 | TP53 (0.51) | ALOX5NPC1ALDH1A1RAB9ATP53 | |
| SCHEMBL9834690 | 0.79 | ALOX5 (0.65) | ALOX5KDM4AKDM4CKDM5APHF8 | |
| SCHEMBL326865 | 0.76 | RAB9A (0.45) | ALOX5L3MBTL1NPC1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015157500-A1 | CLASS IIA HDAC INHIBITORS FOR THE TREATMENT OF INFECTION | RESEARCH DEVELOPMENT FOUNDATION (US) | 2015-10-15 | — | — | WO | claimed |
| CN-101115495-B | Method to enhance the bone formation activity of bmp by RUNX2 acetylation | BIORUNX | 2011-06-22 | — | — | CN | claimed |
| US-20250326771-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | VIIV HEALTHCARE CO (US) | 2025-10-23 | — | — | US | disclosed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| US-12053482-B2 | Oral formulations of cytidine analogs and methods of use thereof | CELGENE CORPORATION (US) | 2024-08-06 | — | — | US | disclosed |
| US-11730736-B2 | Anticancer agents | RAPT THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| WO-2023017179-A1 | METHYLENE QUINUCLIDINONE COMPANION DIAGNOSTICS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2023-02-16 | — | — | WO | disclosed |
| US-11571436-B2 | Oral formulations of cytidine analogs and methods of use thereof | CELGENE CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-11554123-B2 | Compositions and methods for reactivating latent HIV-1 infections | SAINT JOSEPH'S UNIVERSITY (US) | 2023-01-17 | — | — | US | disclosed |
| US-20100184812-A1 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-07-22 | — | — | US | disclosed |
| EP-2167090-A2 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | University of Maryland, Baltimore (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090286752-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2009-11-19 | — | — | US | disclosed |
| WO-2009126662-A1 | ADMINISTRATION OF AN INHIBITOR OF HDAC, AN INHIBITOR OF HER-2, AND A SELECTIVE ESTROGEN RECEPTOR MODULATOR | SYNDAX PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-1692097-B1 | TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS | EXONHIT THERAPEUTICS SA (FR) | 2009-09-02 | — | — | EP | disclosed |
| WO-2009065926-A2 | NEW ANTICANCER COMPOUNDS | SULFIDRIS S.R.L. (IT) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009064300-A1 | COMBINATIONS OF HDAC INHIBITORS AND CYTOKINES/GROWTH FACTORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-2022492-A1 | Anti-cancer pharmaceutical composition | Pianezza, Maurizio (IT) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008154402-A2 | HDAC INHIBITORS AND HORMONE TARGETED DRUGS FOR THE TREATMENT OF CANCER | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326771-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | CCR5, THPO, IL5 | ALOX5 1735/4885KDM4A 2433/4885KDM4C 1838/4885 |
| US-12053482-B2 | Oral formulations of cytidine analogs and methods of use thereof | DCTD, CDA, NT5C2 | ALOX5 725/4885KDM4A 3061/4885KDM4C 1789/4885 |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | ALOX5 725/4885KDM4A 3061/4885KDM4C 1789/4885 |
| US-20090286752-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | ALOX5 725/4885KDM4A 3061/4885KDM4C 1789/4885 |
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | ALOX5 725/4885KDM4A 3061/4885KDM4C 1789/4885 |
| US-11571436-B2 | Oral formulations of cytidine analogs and methods of use thereof | DCTD, CDA, NT5C2 | ALOX5 725/4885KDM4A 3061/4885KDM4C 1789/4885 |
| US-20100184812-A1 | MUTUAL PRODRUGS AND METHODS TO TREAT CANCER | RARA, RARB, RARG | ALOX5 1186/4885KDM4A 74/4885KDM4C 165/4885 |
| US-20240325398-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | ALOX5 3730/4885KDM4A 334/4885KDM4C 492/4885 |
| US-11730736-B2 | Anticancer agents | CCR4, CCR3, CCR1 | ALOX5 4026/4885KDM4A 1609/4885KDM4C 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.